Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
Matthew Dankner(McGill University), April A. N. Rose(Jewish General Hospital), Dan Moldoveanu(McGill University Health Centre), Kevin Petrecca(McGill University Health Centre), Mathieu Lajoie(McGill University Health Centre), Xiu Huang(Nickel Institute), Paul Savage(Unknown), Ian R. Watson(McGill University), Shivshankari Rajkumar(McGill University Health Centre), Catalin Mihalcioiu(McGill University Health Centre), David Hogg(University of Leeds), Peter M. Siegel(L'Oréal (France)), Tan-Trieu Nguyen(McGill University Health Centre), Morag Park(McGill University Health Centre), Maria Lvova(Nickel Institute), Alexei Protopopov, Marie‐Christine Guiot(McGill University), Dana Vuzman
Cited by 76
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
|Cancer Cell|2017|656
Intraoperative brain cancer detection with Raman spectroscopy in humans
|Science Translational Medicine|2015|625